The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the first patient has been dosed in ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...

"CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed ... open-label study designed to evaluate the safety and efficacy of MB-105 in ...

“CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias ... in patients with relapsed or refractory CD5-positive T-cell lymphoma. It will enroll approximately ...

are highly aggressive and generally exhibit a poorer prognosis than their B‑cell counterparts with limited treatment options. Aimed at expanding possibilities for NK‑cell therapies, GCC2005 is an ...